Jazz Pharmaceuticals JAZZ Zepzelca — Revenue from Contract with Customer, Excluding Assessed Tax
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's zepzelca — revenue from contract with customer, excluding assessed tax.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's zepzelca — revenue from contract with customer, excluding assessed tax?
- Jazz Pharmaceuticals (JAZZ) reported zepzelca — revenue from contract with customer, excluding assessed tax of $101M in Q1 2026.
- How has Jazz Pharmaceuticals's zepzelca — revenue from contract with customer, excluding assessed tax changed year-over-year?
- Jazz Pharmaceuticals's zepzelca — revenue from contract with customer, excluding assessed tax increased by 60.3% year-over-year, from $63M to $101M.
- What is the long-term trend for Jazz Pharmaceuticals's zepzelca — revenue from contract with customer, excluding assessed tax?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's zepzelca — revenue from contract with customer, excluding assessed tax has grown at a 5.6% compound annual growth rate (CAGR), from $246.81M to $307.28M.
- What does zepzelca — revenue from contract with customer, excluding assessed tax mean?
- The total net sales revenue generated specifically from the oncology drug Zepzelca.
- How do you interpret zepzelca — revenue from contract with customer, excluding assessed tax?
- An increase indicates growing market penetration, successful clinical adoption, or expanded patient access for the therapy, while a decrease may signal increased competition, patent expiration, or shifts in clinical treatment guidelines.
- How does zepzelca — revenue from contract with customer, excluding assessed tax compare across companies?
- Comparable to product-specific net sales figures reported by other biopharmaceutical companies for their key oncology or specialty therapeutic assets.